Bryostatins, macrocyclic lactones from the marine bryozoan Bugula neritina, are potent antineoplastic agents and multipotential stimulators of immune cells. We have examined the effects of bryostatins on mediator release from human basophilic leukocytes and human tissue mast cells. Bryostatins 1.2, and 5 (10 t o 3,000 nmol/L) induced histamine secretion from purified and unpurified peripheral blood basophils, whereas they caused no release of peptide-leukotriene C, from these cells. The rate of histamine release caused by bryostatin 1 was slower than that caused by anti-lgE It'/, r SEM = 38.2 f 4.7 minutes v 8.9 2 0.2 minutes; P < .01), whereas the temperature dependence was similar (optimum release at 37°C. approximately 30% less at 30°C. and no release at 22°C or 4°C). The addition of increasing concentrations of extracellular Ca2+ to the medium caused histamine release in the presence of bryostatins. Subeffective concentrations of bryostatins and anti-lgE produced a synergistic effect on histamine release from basophils. Staurosporine, ROTEIN KINASE C (PKC) regulates a number of cellular responses associated with growth and differentiation.' Moreover, PKC participates in signal transduction cascades and cell activation in many cell types, including immune and inflammatory cells.',' PKC is activated indirectly by hormones and growth factors that enhance phospholipase C activity. PKC is also the receptor for phorbol ester tumor promoters: which have been used to identify the role of this enzyme in cell proliferation, differentiation, and activation. Another class of compounds that bind to and activate PKC are bryostatins, a family of structurally related macrocyclic lactones isolated from the marine bryozoan Bugula neritina that possesses potent antineoplastic proper tie^.^ Bryostatins have received considerable attention because they show a greater selectivity of responses than phorbol esters. For instance, bryostatin 1 behaves either as an agonist or as an antagonist for PKC-mediated responses.',' Several models have been proposed for the different selectivities of bryostatins, phorbol esters, and dia~ylglycerol."~ Bryostatins are also of interest due to the series of structurally related molecules that have been isolated, all of which 0006-4971/95/8505-0022$3.00/0 1272 chelerythrine, and calphostin C (0.1 t o 10 nmol/L), which are protein kinase C inhibitors, inhibiited the histamine secretion activated by bryostatin 1 and tetradecanoylphorbol-acetate ITPA). Preincubation with granulocyte-monocyte colonystimulating factor (GM-CSF; 1 and 5 nmol/L) and interleukin-3 (IL-3; 10 ng/mL) potentiated the activation of human basophils induced by bryostatin 1. Neither bryostatin 1 nor bryostatin 2 induced the release of histamine from mast cells isolated from human lung or skin tissues. However, brief ( l 0 minutes) preincubation with bryostatin 1 (3 t o 300 nmol/L) potently inhibited the histamine secretion induced by antiIgE from skin or lung mast cells. Bryostatin 1 was a more potent (by approximately 30 times) inhibitor of IgE-mediated histamine release than was TPA. The heterogeneous effects exerted by bryostatins on human basophils and mast cells can be of interest for those designing therapeutic trials using these agents.
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bind with high affinity to PKC and activate this enzyme.'"," Although most of the work with bryostatins has been performed with bryostatin 1, there is evidence that bryostatin 2 differs from bryostatin l structurally and biologically." Furthermore, there is evidence that bryostatins activate or modulate B and T lymphocyte^,".'^ monocytic cell lines: granulocytes,' bas~phils,'~.'' and eo~inophils.'~ Clinical trials assessing the therapeutic effect of bryostatin l in malignant tumors are in an advanced stage," and the results are promising."
The release of histamine and other mediators from peripheral blood basophils and tissue mast cells is an important event in many immunologic responses.'" These cells release proinflammatory mediators when challenged with a variety of stimuli, including antigen, anti-IgE, and tumor-promoting phorbol diesters.*("" Human mast cells and basophils also synthesize, under appropriate circumstances, cytokines such as interleukin-4 (1L-4).'4,2' This implies that these cells can play a central role in chronic inflammatory and immunologic diseases. In addition, basophil and mast cell recruitment and activation may be important in the reactions to certain neoplasms in animalsz6 and in Therefore, we examined the effects of bryostatins l , 2, and 5 on the release of preformed (histamine) and de novo synthesized chemical mediators (peptide-leukotriene C,; LTC,) from human basophils and mast cells. We have also studied the interactions of these antineoplastic agents with immunologic stimuli (anti-IgE) and various cytokines [IL-3, IL-5, and granulocyte-monocyte colony-stimulating factor (GM-CSF)I.
human serum albumin (HSA) and 3.42 g/L sodium citrate and were loaded onto a countercurrent elutriator (model 52-21. Beckman Instruments, Fullerton, CA). Several fractions were collected, and fractions containing basophils in large numbers (greater than 20 X lo6 basophils) and of improved purity (greater than 15%) were further enriched by discontinuous Percoll gradients. Basophil yields by this technique ranged from 3 X IO6 to 8 X lo6, and purities from 75% to 90%, as assessed by basophil staining with Alcian blue and counting in a Spiers-Levy eosinophil ~ounter.~' Isolation of human lung and skin mast cells. Human lung tissue was obtained from patients undergoing thoracotomy and lung resection, mostly for lung cancer. The study protocol was approved by the Ethics Committee for Human research of the University of Naples Federico I1 School of Medicine. Macroscopically normal lung tissue was dissected free from pleura, bronchi, and blood vessels, minced into 5-to IO-mm fragments, and dispersed into single-cell suspension as previously des~ribed.'~,~~ Mast cell yieIds with this technique ranged between 3 X IO6 and 20 X IO6, and purities ranged between 1% and 8%. Skin tissue was obtained from patients undergoing mastectomies for breast cancer. Tissue was immediately placed in minimal essential medium (MEM) at 4°C and used within 3 hours. The skin was separated from the subcutaneous fat by blunt dissection. The remaining tissue was cut into 1-to 2-mm fragments with scissors. The fragments were washed twice in Caz'-and Mgzf-free Hanks' balanced salt solution (HBSS) at 22°C and incubated for 3 hours at 37°C under constant stirring in Caz+-and Mgz'-free HBSS containing (per gram of wet tissue) 2,500 U collagenase, 5 mg hyaluronidase, and 1,000 U deoxyribonuclease I.34,3s The isolated cells were separated from the partially digested tissue fragments by filtration through Nytex cloth (150-pm pore size) and stored (Tetko, Elmstard, NY). The remaining tissue was digested a second time for a further 2 hours at 37°C. The cells were separated from the tissue fragments by filtration through a 150-pm pore Nytex cloth, washed twice, combined with the cells from the first digestion, and washed again in Ca2+-and Mg2+-free HBSS. Mast cell yields with this technique ranged between 1 X IO6 and 20 X IO6, and purities were between 1 % and 6%. Mast cells were stained with Alcian blue and counted in a Spiers-Levy eosinophil counter.32 Bryostatins did not affect viability of human mast cells and basophils as assessed by trypan blue exclusion (data not shown).
Histamine release assay. In experiments with basophils (approximately 6 X lo4 basophils per tube), purified or not purified, or mast cells (approximately 3 X IO4 mast cells per tube), cells were resuspended in P2CG, and 0.1 mL of the cell suspension was placed in 12 X 75-mm polyethylene tubes (Sarstadt Inc, Princeton, NJ) and warmed to 37°C; 0.2 mL of each prewarmed stimulus for release was added, and incubation was continued at 37°C for 60 minutes, unless indicated differently. At the end of this step, the reaction was stopped by centrifugation (1, OOOg at 22°C for 2 minutes), and the cell-free supernatants were stored at -20°C for subsequent assay of histamine and LTC, content. The cell-free supernatants were assayed for histamine with an automated fluorometric technique." To calculate histamine release as a percentage of total cellular histamine, the spontaneous release of histamine from basophils or mast cells (0 to 10% of the total cellular histamine) was subtracted from both numerator and denominator. The percent histamine release was calculated according to the following equation:
where A is the sample, B is the spontaneous histamine release, and T i s the total histamine content. 1 or TPA were characterized by median dose-effect analysis as described by Chou and Talalay" and processed using commercially available software (Dose-Effect Analysis; Biosoft, Cambridge, UK). The combination index (CI) values for this combination of stimuli were determined using either mutually exclusive or nonexclusive assumptions. A C1 value lower than 1 denotes a synergistic interaction.
RESULTS

Activation of human basophils induced by bryostatins.
In a first group of experiments, we assessed the effects of increasing concentrations of bryostatins 1, 2, and 5 on histamine release from purified peripheral blood basophils (75% to 90% pure) obtained from normal donors. In a series of six experiments, bryostatin 1 (10 to 1,000 nmol/L), bryostatin 2 (10 to 3,000 nmol/L), and bryostatin 5 (10 to 3,000 nmoV L) concentrations dependently caused histamine release from basophils. As previously reported, TPA (15 to 500 nmoVL) induced the release of histamine from basophils (Fig 1) . Bryostatin 1 was a more potent activator than was TPA, while bryostatins 2 and 5 were much less potent than the other two stimuli. The maximal histamine release induced by bryostatin 1 and TPA was similar (approximately 60% while bryostatins 2 and 5 were much less effective (maximal response, approximately 20%). Similar results were obtained in a series of eight experiments in which unpurified (approximately 1% pure) basophils were used (data not shown).
Characteristics of bryostatin-induced histamine release. We next compared the kinetics of histamine release induced by bryostatins, TF' A, and anti-IgE from basophils. The time course of histamine release induced by bryostatins 1 and 2 was slow, reaching a maximum at 40 to 60 minutes after the addition of the stimulus. As previously shown,30 antiIgE-induced histamine release was significantly faster, being complete after 15 minutes (Fig 2) . Bryostatin 5-induced histamine release was extremely slow, reaching its plateau after 90 minutes. The t'h of the release reaction induced by 
We studied the histamine-releasing activity of bryostatin 1 on basophils incubated at 37"C, 30°C, 22"C, and 4°C. Figure 3 shows that the bryostatin l-induced response was abolished by lowering the temperature of the incubation buffer from 37°C to 22°C or 4°C and decreased approximately 30% at 30°C. Similar results were obtained in two other experiments.
EfSeect ofextracellular eaZC on the histamine releasefrom basophils by bryostatins. We also investigated the effect of the presence of increasing concentrations of extracellular Ca2' (0.1 to 5 mmolL) on the histamine-releasing activity of bryostatin 1 and bryostatin 2 (Fig 4) . The presence of increasing concentrations of extracellular Ca2+ increased the percent histamine release induced by bryostatin l and bryostatin 2. All subsequent experiments were conducted with physiologic concentrations of extracellular Ca2+ (2 mmo1L).
Effect of bryostatin l on LTC4 release. The immunologic activation of human basophils leads to de novo synthesis and release of LTC, through the 5-lipoxygenase pathway'" in addition to the secretion of preformed histamine. In a series of four experiments, we compared the effects of various concentrations of bryostatin 1, TPA, and anti-IgE on the release of LTC4 from basophils. As previously demonstrated with TPA;' optimal concentrations of bryostatin l (30 to 1,000 nmoVL) did not induce the release of LTC, from peripheral blood basophils (Table l) . In a control experiment.
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Synergy between bryostatin I and anti-IgE. Anti-IgE, which induces histamine release by crosslinking cell surface IgE, was tested for synergy with bryostatin 1 and TPA. Table  2 shows that the presence of bryostatin 1 potentiated the anti-IgE-induced release of histamine from basophils. A potentiation of release was detected at each condition studied in all three experiments. As previously reported:' TPA also potentiated anti-IgE-induced histamine release from basophils. Similar results were obtained with bryostatin 2 (data not shown). Effects of staurosporine, chelerythrine, and calphostin C. We next examined the effects of staurosporine and two more specific PKC inhibitors, chelerythrine and calphostin C: z4 on bryostatin 1-, TPA-, and anti-IgE-induced histamine release from basophils. Pretreatment (15 minutes) of basophils with staurosporine, chelerythrine, and calphostin C (0.1 to 10 nmoVL) inhibited bryostatin 1-and TPA-induced histamine release in a concentration-dependent fashion (Fig 6) . These experiments were performed in the light because calphostin C is known to be light-a~tivated.~' The concentrations (mean ? SEMI required to reduce histamine release by 50% (I&) were 1.5 t-0.7 nmol/L and 3.6 2 0.7 nmoV L (staurosporine), 6.8 ? 4.4 nmom and 6.6 2 4.1 nmol/L (chelerythrine), and 2.2 t-1.7 nmol/L and 9.3 -t-2.1 nmoV L (calphostin C) when cells were activated by bryostatin 1 and TPA, respectively. As previously reported, staurosporine?6 chelerythrine, and calphostin CM had some inhibitory effect on anti-IgE-induced histamine release from basophils. However, the potency of these drugs was much reduced; indeed, the IC35 for anti-IgE (4.5 ? 0.9 nmol/L, 5.1 2 2.8 nmol/L, and 5.1 t-2.9 nmol/L for staurosporine, chelerythrine, and calphostin C, respectively) was greater than in bryostatin l-induced (1.3 t-0.6 nmol/L, 2.8 -t-1.9 nmol/L, and 0.15 -t-0.1 nmol/L; P < .05) and TPA-induced Figure 7A shows that preincubation of basophils with GM-CSF (1 and 5 nmom) concentration dependently potentiated the release of histamine caused by bryostatin 1 (10 to 300 nmoVL). The priming effect of GM-CSF was observed even at concentrations of bryostatin 1 (10 nmoVL) that caused no histamine release. Similar results were obtained with IL-3 (10 ng/mL) but, interestingly, not with IL-5 (10 U/mL; Fig 7B) . In these experiments, IL-3, IL-5, and GM-CSF alone did not activate purified basophils (Fig 7A and B) .
Effect of bryostatins on human mast cells isolated from human lung and skin. Given the heterogeneity of human basophils and mast cells,s' we tested whether bryostatins could induce histamine release from human lung or skin mast cells and compared their effects with anti-IgE and calcium ionophore A23187. Figure 8 shows that a wide range of concentrations of bryostatins 1 and 2 (30 to 3,000 nmol/L) did not affect the secretion of histamine from either human lung (Fig 8A) or skin mast cells (Fig 8B) . In contrast, both of these mast cell types responded to a challenge with optimal concentrations of anti-IgE or A23187 with a concentrationdependent release of histamine (Fig 8A and B) . TPA alone did not activate human lung and skin mast cells (data not shown).
Effect of bryostatin l on IgE-mediated histamine release from human mast cells. It has been previously shown that prolonged pretreatment ( l 8 hours) of human mast cells with the PKC activator TPA inhibits the subsequent response to anti-IgE.4' We compared the effect of brief preincubation (10 minutes) with low concentrations of bryostatin 1 (0.1 to 300 nmol/L) and TPA (0.1 to 300 nmol/L) on the secretion of histamine from skin mast cells induced by anti-IgE. Figure  9 shows that both TPA and bryostatin 1 caused a concentration-dependent inhibition of IgE-mediated response of skin mast cells. 1nterestingiy;bryostatin 1 was a much more potent inhibitor (approximately 30-fold) than TPA (ICjs = 6.3 f 1.2 nmol/L v 200 +-11.1 nmol/L; P < ,001 ). Similar results were obtained in three experiments with human lung mast cells (data not shown). Brief (10-minute) incubation of human lung mast cells with bryostatin 1 or TPA did not affect A23187-induced histamine release (data not shown).
We also evaluated the kinetics of the inhibition of IgEmediated histamine release by bryostatin l (100 nmol/L) in human lung and skin mast cells. In the preincubation time range between IO and 120 minutes, we found no significant differences in the inhibiting effect of bryostatin I in human lung and skin mast cells (n = 3; data not shown). 
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and bryostatin's releasing activity from basophils was temperature-dependent. Indeed, bryostatin releasing activity was blocked by incubation at a low temperature (22°C and 4°C) and was markedly reduced by lowering the temperature from 37°C to 30°C. A noncytotoxic mechanism is also suggested by the lack of cytotoxicity of similar concentrations of bryostatins in systems using other immune cells (such as neutrophils, lymphocytes, et^)."'^.'^ The kinetics and Ca2' dependence of basophil activation induced by bryostatins differed markedly from anti-IgE-induced release, but are similar to TPA-induced secretion of histamine from basophils." The kinetics of basophil activation by different bryostatins vary to some extent, with bryostatin 5 being the slowest activator of human basophils. Bryostatins act as incomplete secretagogues on human basophils (no release of LTCJ, as previously shown for TPA.4" As similar results were obtained with highly purified and unpurified basophils, it is likely that bryostatins activate directly peripheral blood basophil. However, the possibility cannot be excluded that bryostatins, which induce the release of specific granules from human ne~trophils,~ might induce the secretion of histamine from basophils through the activation of neutrophils or other contaminating cells.
It is not unfeasible that the mechanism of activation of basophils could be mediated by interaction of bryostatins with PKC. In this context, appropriate concentrations of staurosporine and two more specific PKC inhibitors, chelerythrine and calphostin C, inhibited mediator release caused by bryostatin 1 and TPA. Although direct measurements of PKC activation by bryostatins were not made, basophils activated by anti-lgE appeared less sensitive to the modulation of staurosporine.
A potentially relevant finding of this study is the synergy between bryostatin 1 and immunologic stimuli or cytokines. We found that pretreatment with bryostatins I and 2 synergistically potentiated the immunologic release of histamine induced by anti-IgE; even low concentrations of bryostatins 1 and 2 that alone caused little or no release of histamine markedly potentiated the releasing activity of anti-IgE on basophils. Another interesting interaction occurs between cytokines and bryostatins. Preincubation of cells with such calcium ionophore A231 87. These results agree with the observation that another PKC activator, TPA, is also unable to induce mediator release from human mast cells.43 Interestingly, low concentrations of bryostatin 1 rapidly and potently inhibited the IgE-mediated activation of human skin and lung mast cells. These results are compatible with the hypothesis that PKC plays a role in the release process of human mast cells induced by IgE crosslinking, because it has been shown that short-term treatment with bryostatin 1 causes rapid loss of PKC a c t i~i t y .~~,~~ Our results extend the observation by Massey et a14" in that it appears that even short-term (10 minutes) cell pretreatment with bryostatin 1 or TPA can cause inhibition of IgE-mediated mast cell activation. Therefore, it is conceivable that downregulation of PKC after brief incubation with bryostatin 1 causes a diminished mast cell response to anti-IgE. Direct PKC measurements cannot yet be performed because they require large amounts of highly purified mast cells that are not currently available from human tissues. The finding that bryostatin 1 was more potent than TPA as an inhibitor of IgEmediated histamine release from skin mast cells is intriguing. In fact, it has been hypothesized that bryostatin 1 and TPA may act on different PKC isozyrnes,l3 or that the two compounds may differ in their affinity to PKC. 55 Mast cells and basophils are commonly considered to play a major role in the pathogenesis of IgE-dependent immediate hypersensitivity."." However, increasing evidence showing that human basophils and mast cells are sources of multifunctional c y t o k i n e~~~~~~ implies that they play a more complex role in the immune regulation than originally thought.
In particular, there is preliminary evidence that basophils and mast cells. through the release of chemical mediators and cytokines, might affect angiogenesis, tumor development, and tumor r e s i s t a n~e .~' ,~~ Bryostatin 1 has been shown to possess in vitros8 and in vivo59 antineoplastic activities, and recent findings suggest that bryostatins represent clinically attractive agents useful for treatment of various neoplasms.'* Previous findings have clearly demonstrated that bryostatin 1 causes substantial activation of T lymphocytes,'" B lymphocytes,14 ne~trophils,~ and ba~ophils.'~,'' The releasing activity of various bryostatins is similar but not identical, and bryostatin 1 appears to be more potent than the tumor promoter TPA. Previous studies have demonstrated that bryostatins bind to and activate PKC, but they differ from TPA in selectivity and in that they behave either as agonists or antagonists of PKC actions.9.6" The basis for the different selectivities of bryostatins and phorbol esters is not ~n d e r s t o o d .~.~ Differences in the activating properties of different bryostatins have been already rep~rted.'~ Here we show that in activating human basophils, different bryostatins also differ in their potency and in some biochemical characteristics. Therefore, further studies of bryostatins as activators of human basophils should be profitable in the understanding of the mechanisms by which bryostatin-sensitive PKC is distinct from TPA-sensitive kinases in basophils. It is fascinating that in the human mast cells bryostatin 1 does not cause activation but, rather, inhibition of the IgEmediated mediator release.
This finding may indicate that downregulation of PKC can play an inhibitory role in mast cell activation induced by anti-IgE. This inhibitory effect of low concentrations of bryostatin 1 in human mast cells might be clinically relevant, because mast cells represent a major source of mediators.
The differential effects of bryostatins on human basophils and mast cells and their complex interaction with other immunologic stimuli or cytokines raise important issues that will need to be considered when designing clinical trials to evaluate the antineoplastic properties of these compounds. For personal use only. on September 24, 2017. by guest www.bloodjournal.org From
